Why EW Healthcare Partners Is Buying TherapeuticsMD (TXMD) In A $177 Million Deal

By Amit Chowdhry ● May 31, 2022
  • TherapeuticsMD, Inc. (NASDAQ: TXMD) announced it entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners as part of a $177 million deal. These are the details.

TherapeuticsMD, Inc. (NASDAQ: TXMD) entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, which is a private equity firm dedicated to making investments in rapidly growing healthcare companies.

Under the terms of the deal, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding shares of TXMD common stock for $10. per share in an all-cash transaction, followed immediately by a merger. The purchase price represents a premium of 367.3% over TherapeuticsMD’s closing share price on May 27, 2022.

EW Healthcare Partners is one of the largest and oldest private healthcare investment firms with over $4 billion of capital raised since its inception. And EW Healthcare Partners has made investments in over 150 rapidly growing healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe.

Deal Details

The deal, which has been unanimously approved by TherapeuticsMD’s Board of Directors, implies a total enterprise value for the Company of approximately $177 million and will be structured as an all-cash tender offer to acquire all issued and outstanding shares of TherapeuticsMD common stock, followed immediately by a merger.

Under the terms of the deal, an affiliate of EW Healthcare Partners will commence a tender offer to acquire all issued and outstanding shares of TherapeuticsMD common stock at a price of $10.00 per share. And the tender offer will initially remain open for 20 business days from the date of commencement of the tender offer, subject to extension under certain circumstances.

The price represents a 367.3% premium over TherapeuticsMD’s closing share price of $2.14 on May 27, 2022, and a premium of 211.8% to TherapeuticsMD’s 30-day volume-weighted average share price on May 27, 2022.

Following successful completion of the tender offer, including meeting certain conditions, the EW Healthcare Partners affiliate will acquire all remaining untendered shares of TherapeuticsMD common stock at the same price of $10.00 per share through a second-step merger.

In connection with entering into the deal, the lenders and administrative agent under the company’s financing agreement with Sixth Street Partners have agreed to extend the maturity date of the Financing Agreement to July 13, 2022, allowing the company to complete the deal with EW Healthcare Partners on or before that date. In addition, the lenders and administrative agent have agreed to roll over the Company’s indebtedness under the financing agreement in connection with, and conditioned on, the closing of the merger.

The closing of the tender offer and merger are subject to certain conditions, including that a majority of the shares of TherapeuticsMD’s common stock are tendered and not withdrawn in the tender offer, that there is no default or event of default under the company’s financing agreement, and other customary closing conditions. Upon completion of the deal, TherapeuticsMD will become a privately held company and shares of TherapeuticsMD’s common stock will no longer be listed on any public market. The parties anticipate that the combination will be completed on or before July 13, 2022.

KEY QUOTES:

“We are very pleased to enter into this agreement with EW Healthcare Partners. Together, we will continue empowering women of all ages through a therapeutic focus in family planning, reproductive health, and menopause management. We have a deep appreciation for EW Healthcare Partners’ depth of expertise and track record and know they will bring an incredible value of knowledge and strategic guidance.”

— Hugh O’Dowd, Chief Executive Officer of TherapeuticsMD

“We are pleased to welcome TherapeuticsMD to the EW Healthcare Partners portfolio and are deeply committed to the Company’s mission of advancing women’s health. EW Healthcare Partners has already made a significant investment in women’s health through its acquisition of Majorelle. TherapeuticsMD represents a unique opportunity for Majorelle to enter the US market and is a perfect fit with our ambitious plans to create a fast-growing, premier trans-Atlantic women’s health platform. We bring an extensive network and capital to fund the further growth of the combined company.” 

— Evis Hursever, Managing Director at EW Healthcare Partners

“We look forward to working together with the company’s management team to enhance the patient experience, improve operational efficiency and create one of a very few trans-Atlantic specialty pharma companies dedicated to women’s health.” 

— Olivier Bohuon, Senior Adviser with EW Healthcare Partners and Chairman of Majorelle

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.